Clinical trials: Left Ventricular Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Cardiomyopathy, Diabetic
CARdiomyopathy in Type 2 DIAbetes Mellitus
The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering approaches based on deep phenotyping (clinical…
- Trial name
- CARDIATEAM (NCT04303364)
- Where
- 17 sites in France, Germany and 3 more
- Volunteers
- 1,256 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Heart Failure With Reduced Ejection Fraction
Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- NCT06851949
- Testing
- Vsling
- Where
- 5 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Cardiac Success
Heart Failure With Preserved Ejection Fraction, Obesity, Mild
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Study Aim is creation of the Hospital Register of patients with heart failure with preserved ejection fraction (HFpEF) for a comprehensive assessment of the influence of gender characteristics, clinical and anamnestic factors…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Obesity, Mild, Decompensated Heart Failure
- Trial name
- NCT06114498
- Testing
- Echocardiography, Bioimpedance, Immunoassay
- Where
- 2 sites in Russia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Central Sleep Apnea, Heart Failure With Preserved Ejection Fraction
Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV
The main goal of this French multicenter observational cohort study is to prospectively collect data assessing the impact of the Adaptative Servo-Ventilation treatment on the quality of sleep of patients with central or combined…
- Trial name
- FACIL-VAA (NCT02835638)
- Testing
- Adaptative Servo Ventilation
- Where
- 28 sites in France
- Volunteers
- 520 people
- Sponsor
- Société Française de Recherche et de Médecine du Sommeil
Cardiac Conduction System, His Bundle Pacing
High Intensity His Bundle Pacing in Heart Failure Patients With Narrow QRS Outcome Study
Cardiac Resynchronization Therapy (CRT) decreases heart failure hospitalizations and mortality and increases left ventricular Ejection Fraction (EF) in patients with dilated cardiomyopathy, left bundle branch block and QRS…
- Conditions
- Cardiac Conduction System, His Bundle Pacing, Heart Failure, Cardiomyopathies
- Trial name
- HIPPOS (NCT05491655)
- Testing
- High Intensity His Bundle pacing
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Miulli General Hospital
Heart Disease, Stroke
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function.
- Conditions
- Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
- Trial name
- WARCEF (NCT00041938)
- Testing
- aspirin, Warfarin
- Where
- 64 sites in United States, Canada
- Volunteers
- 2,305 people
- Sponsor
- Columbia University
Heart Failure
Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)
Participants with heart failure with preserved ejection fraction will undergo 12 weeks of cardiac rehabilitation for exercise training (ET) and be randomized to either sodium nitrite or placebo through the training period.
- Trial name
- INABLE (NCT02713126)
- Testing
- Sodium Nitrite, Accelerometer, Cardiac Exercise Training
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Barry Borlaug
Diastolic Heart Failure NYHA Class III-IV, Diastolic Dysfunction Secondary to Aortic Stenosis
CORolla™ TAA for Heart Failure and Preserved Ejection Fraction and Diastolic Dysfunction
The study purpose is to evaluate the safety and feasibility of the CORolla™ TAA in two treatment groups, "CORolla™ Stand-alone group" and " AVR \& CORolla™ Add on group".
- Trial name
- NCT01956526
- Testing
- CORolla™ TAA device
- Where
- 2 sites in Italy
- Volunteers
- 12 people
- Sponsor
- CorAssist Cadiovascular Ltd.
Heart Failure
Impact of Vericiguat on Hemodynamics of Heart Failure
Vericiguat is a new drug that was recently approved by the Food and Drug Administration for patients with heart failure. In a large randomized controlled trial, this drug was found to help patients with heart failure live longer…
- Trial name
- NCT05704478
- Testing
- Vericiguat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Heart Failure Preserved Ejection Fraction, Pregnancy Complications
Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction
Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease.
- Trial name
- MAPO-HF (NCT06338943)
- Testing
- Echocardiography, Questionnaire
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Pulmonary Hypertension, Heart Failure
Metformin for Pulmonary Hypertension HFpEF
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
- Trial name
- PH-HFpEF (NCT03629340)
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Francisco
Heart Failure With Preserved Ejection Fraction
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
This study is being done to evaluate the effects of a low carbohydrate ketogenic diet (KD) versus a low-fat diet (MD) on exercise tolerance in participants with heart failure with normal pumping function and diabetes or…
- Trial name
- NCT06081543
- Testing
- Ketogenic diet, Low-fat Mixed diet
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ohio State University
Transthyretin Amyloid Cardiomyopathy, Heart Failure
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
Clinical comparison of patients with transthyretin cardiac amyloidosis and patients with heart failure with reduced ejection fraction
- Trial name
- NCT05896904
- Testing
- Echocardiography
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Aarhus University Hospital Skejby
Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
In patients with heart failure due to a reversible underlying cause-such as valvular heart disease or coronary artery disease-surgical or procedural correction of the underlying lesion (valve repair/replacement, TAVI, PCI, or…
- Conditions
- Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy, Heart Failure
- Trial name
- NCT07572032
- Testing
- Sacubitril / Valsartan, SGLT-2 inhibitor, SGLT2 Inhibition
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Atrial Fibrillation (AF), Hart Failure
Heart Failure Biomarkers
Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE.
- Trial name
- BIOHF (NCT06616038)
- Testing
- Data collection
- Where
- 2 sites in Italy
- Volunteers
- 114 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Heart Failure
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood…
- Trial name
- FINEARTS-HF (NCT04435626)
- Testing
- Finerenone (BAY94-8862)
- Where
- 661 sites in United States, Argentina and 35 more
- Volunteers
- 6,016 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
- Trial name
- NCT07599293
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 39,614 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
Staging Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is considered a systemic condition in which the prevalence of cardiovascular, metabolic, pulmonary and renal conditions determine the extent of cardiac involvement.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Failure
- Trial name
- StageHFpEF (NCT06931015)
- Testing
- No interventions
- Where
- Russia
- Volunteers
- 700 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
This is a randomized study of ambrisentan that will last 16 weeks. The study will include patients with diastolic heart failure and pulmonary hypertension. Patients will be randomized (1:1) to ambrisentan or placebo.
- Trial name
- NCT00840463
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center